Topic

What’s different (and not) about injecting GA drugs

Tips for injecting pegcetacoplan and avacincaptad pegol for geographic atrophy.

Companies are attacking the disease from multiple angles.

Biosimilars are reducing costs and increasing access, but in retina they also face unique challenges compared with other medical specialties.

This modality may help decrease the treatment burden.

Here’s what we know about the new high-dose aflibercept based on the pivotal trials.

Geographic atrophy continues to be the fastest-growing area of interest, and new entries double the number of dropouts.

A review of how a variety of immunotherapy and targeted therapies for cancer can impact the retina and the rest of the eye.

A look at the benefits and drawbacks of the three dominant modalities in clinical trials.

Exits for discontinued programs (three over two years) exceed exits for approvals (two).

Immune checkpoint inhibitors are becoming more widely available, but they’ve been linked to uveitis in some patients.